- Home
- BLTE vs DEI Comparison
BLTE vs DEI Comparison
Compare BLTE & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- DEI
- Stock Information
- Founded
- BLTE 2018
- DEI 1971
- Country
- BLTE United States
- DEI United States
- Employees
- BLTE N/A
- DEI N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- DEI Real Estate Investment Trusts
- Sector
- BLTE Health Care
- DEI Real Estate
- Exchange
- BLTE Nasdaq
- DEI Nasdaq
- Market Cap
- BLTE 2.1B
- DEI 2.4B
- IPO Year
- BLTE 2022
- DEI 2006
- Fundamental
- Price
- BLTE $65.74
- DEI $16.89
- Analyst Decision
- BLTE Strong Buy
- DEI Hold
- Analyst Count
- BLTE 4
- DEI 10
- Target Price
- BLTE $96.67
- DEI $18.11
- AVG Volume (30 Days)
- BLTE 39.8K
- DEI 1.4M
- Earning Date
- BLTE 08-11-2025
- DEI 11-03-2025
- Dividend Yield
- BLTE N/A
- DEI 4.52%
- EPS Growth
- BLTE N/A
- DEI N/A
- EPS
- BLTE N/A
- DEI 0.22
- Revenue
- BLTE N/A
- DEI $1,001,173,000.00
- Revenue This Year
- BLTE N/A
- DEI $2.32
- Revenue Next Year
- BLTE N/A
- DEI $2.17
- P/E Ratio
- BLTE N/A
- DEI $77.46
- Revenue Growth
- BLTE N/A
- DEI 3.24
- 52 Week Low
- BLTE $43.70
- DEI $12.39
- 52 Week High
- BLTE $86.53
- DEI $20.50
- Technical
- Relative Strength Index (RSI)
- BLTE 52.03
- DEI 71.45
- Support Level
- BLTE $62.18
- DEI $15.91
- Resistance Level
- BLTE $66.15
- DEI $16.24
- Average True Range (ATR)
- BLTE 2.66
- DEI 0.38
- MACD
- BLTE -0.16
- DEI 0.18
- Stochastic Oscillator
- BLTE 72.80
- DEI 98.11
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About DEI Douglas Emmett Inc.
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.